dr. o’regan on prognostic value of pcr in her2 breast cancer
Published 4 years ago • 461 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
0:52
dr. o'regan on impact of targeted agents in her2 breast cancer
-
1:11
dr. o'regan discusses the future of treatment in her2 breast cancer
-
0:49
dr. o'regan on biomarker research in breast cancer
-
0:54
dr. o’regan discusses updates in her2-positive breast cancer
-
17:53
er-signaling in her2-postive breast cancer - dr. ruth o'regan
-
1:01
dr. han on the importance of pcr in breast cancer
-
0:45
dr. hamilton on using pcr to classify risk in her2 breast cancer
-
1:23
dr. o'regan on endocrine therapy resistance in breast cancer
-
2:30
prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis
-
1:05
dr. o’regan on the mechanism of action of trastuzumab
-
1:14
prognostic value of beta-2 adrenergic receptor levels in her2 breast cancer
-
28:03
triple negative breast cancer - o'regan
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
0:53
prognostic trials for 21-gene oncotypedx in hr /her2- breast cancer with micrometastases
-
1:31
dr. sledge on using pcr to determine therapy benefit for breast cancer
-
4:50
overview of neoadjuvant therapy in her2 breast cancer
-
1:37
dr. bhave on promising anti-her2 agents in her2 breast cancer
-
1:31
dr. loi on immune cells in her2 breast cancer